^
    Back
    Association details:
    Biomarker:TUBA1C overexpression
    Cancer:Bladder Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    BMC Cancer
    Title:

    TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle

    Published date:
    08/01/2023
    Excerpt:
    ...high TUBA1C expression in bladder cancer was associated with a poorer outcome than low expression.
    DOI:
    https://doi.org/10.1186/s12885-023-11209-2